Amdocs Ltd (DOX) stock analysis
Close on Nov 11, 2026Market cap $4.68BP/E 8.5Yield 4.78%
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed10 of 30 checks passed
Amdocs passes 10 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 6/6
- Financial health
- 3/6
- Dividend
- 0/6
What stands out
Return on equity over 15%
Return on equity was 16.4% over the last twelve months and averaged 16.1% over five years.
Return on capital over 10%
Return on invested capital was 15.7%, above the 10% that usually covers the cost of capital.
Low debt
Debt is 18.9% of shareholders' equity, under the 40% we consider low.
Earnings grew over 5 years
Net income grew 2.6% a year on average over the last five fiscal years.
What to watch
Revenue growing under 10% a year
Revenue grew -0.3% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew 4.4% a year over the last three fiscal years.
Growing slower than the industry
Revenue grew -9.4% over the last twelve months; the Computer Programming, Data Processing, and Other Computer Related Services median is 9.6%.
No dividend
Amdocs has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growing under 10% a year
Revenue grew -0.3% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew 4.4% a year over the last three fiscal years.
Earnings growth accelerating
Net income grew 14.5% over the last twelve months, against a 5-year average of 2.6% a year.
Growing slower than the industry
Revenue grew -9.4% over the last twelve months; the Computer Programming, Data Processing, and Other Computer Related Services median is 9.6%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance6/6
Return on equity over 15%
Return on equity was 16.4% over the last twelve months and averaged 16.1% over five years.
Return on capital over 10%
Return on invested capital was 15.7%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Amdocs's return on equity of 16.4% is above the Computer Programming, Data Processing, and Other Computer Related Services median of -1.2%.
Earnings grew over 5 years
Net income grew 2.6% a year on average over the last five fiscal years.
Net margin above its 5-year average
Net margin was 12.5% over the last twelve months, against a 5-year average of 12.3%.
Net margin above the industry
Amdocs's net margin of 12.5% is above the Computer Programming, Data Processing, and Other Computer Related Services median of -4.8%.
Financial health3/6
Low debt
Debt is 18.9% of shareholders' equity, under the 40% we consider low.
Debt falling against equity
Debt to equity fell from 20.5% five years ago to 18.9%.
Debt coverage
Needs operating cash flow.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 1.17 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Amdocs has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Amdocs. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $88.29M
- Value traded per 1% price move
- $51.72M
Downside
Medium risk
- Typical loss in a bad month
- 24.2%
- Volatility (annualized)
- 42%
- Sharpe ratio, 1 year
- -1.28
- Beta to the S&P 500 (5Y)
- 0.63
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -9.4% | -0.3% | +1.7% | +2.2% | |
| Gross profit | -1.9% | +2.1% | +4.0% | +2.9% | |
| Operating income | +16.4% | +3.2% | +4.2% | +3.6% | |
| Net income | +14.5% | +0.9% | +2.6% | +2.4% | |
| EPS, diluted | +18.8% | +4.4% | +6.4% | +5.9% | |
| Free cash flow | +4.2% | +6.8% | – | -0.1% | |
| Dividend per share | +10.0% | +10.1% | +10.2% | +12.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.9% | 14.0% | 16.4% | |
| Return on assets | 7.7% | 8.6% | 8.9% | |
| Current ratio | 1.54 | 1.71 | 1.17 | |
| Debt to equity | – | 0.21 | 0.19 | |
| Net debt to EBITDA | – | -0.30× | – | |
| Interest coverage | 289.8× | 57.0× | 17.2× | |
| Capex to revenue | 3.5% | – | 2.3% | |
| Diluted shares | 150M | 133M | 111M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Amdocs generated $3.98B from operations and spent $4.56B on capital expenditure, dividends and share buybacks. 17% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 12.5% | 0.72× | 1.83× | 16.4% |
| FY2024 | 9.9% | 0.78× | 1.84× | 14.1% |
| FY2023 | 11.1% | 0.76× | 1.82× | 15.4% |
| FY2022 | 12.0% | 0.71× | 1.81× | 15.5% |
| FY2021 | 16.1% | 0.67× | 1.78× | 19.1% |
| FY2020 | 11.9% | 0.72× | 1.63× | 14.0% |
| FY2019 | 11.7% | 0.77× | 1.53× | 13.8% |
| FY2018 | 8.9% | 0.75× | 1.51× | 10.1% |
| FY2017 | 11.3% | 0.73× | 1.51× | 12.4% |
| FY2016 | 11.0% | 0.70× | 1.55× | 11.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$564.70M
- Cash generatingOperating cash flow above zero$749.10M
- Return on assets improvedROA up on the prior year7.7% → 8.8%
- Earnings backed by cashOperating cash flow above net income$749.10M vs $564.70M
- Less leverageLong-term debt to assets fell10.1% → 10.4%
- Better liquidityCurrent ratio rose1.20 → 1.17
- No dilutionShare count did not rise115M → 111M
- Gross margin improvedGross margin up on the prior year35.07% → 37.98%
- More efficientAsset turnover rose0.78 → 0.71
See a number that looks wrong?